Drawing for ELISIGEN

USPTO serial 79458054

ELISIGEN

Reviewed by CopyMark Law Group

Status 640Office Action
Filing date
Status date
Registration date
—
Examiner
LEE, YATSYE ISADORA
Law office
TMEG LAW OFFICE 107

What this means

The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.

Status 640: Status 640 means the examining attorney has prepared a non-final Office Action but it has not been mailed or e-mailed yet. The action should appear in TSDR soon, and a response deadline will start once it is issued.

Need help with ELISIGEN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Nucleic acid sequences for medical and veterinary purposes; chemical reagents for dna analysis for medical purposes; cell therapy preparations for medical purposes; synthetic peptides for pharmaceutical purposes; cells for medical purposes; ophthalmic preparations; pharmaceutical preparations for treating sensory organ disorders; pharmaceutical preparations for treating peripheral nervous system disorders; pharmaceutical preparations for the treatment of tinnitus; pharmaceutical preparations for the treatment of central nervous system diseases and disorders; pain relief medication; analgesics; pharmaceutical preparations for use in immunomodulation therapies; vaccines; tranquilizers; chemical preparations for pharmaceutical purposes; biological preparations for medical and veterinary purposes; diagnostic preparations for medical purposes; drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations; pharmaceutical preparations for the prevention and treatment of allergies.ACTIVE—
035Wholesale distributorships in the field of pharmaceutical preparations for the treatment of sensory organ disorders; wholesale distributorships in the field of pharmaceutical preparations for the treatment of peripheral nervous system disorders; wholesale distributorships in the field of pharmaceutical preparations for the treatment of central nervous system disorders; wholesale distributorships in the field of analgesics; wholesale distributorships in the field of immunomodulators; wholesale distributorships in the field of vaccines; wholesale distributorships in the field of chemical preparations for use in the manufacture of pharmaceuticals; wholesale distributorships in the field of biological preparations for medical and veterinary purposes; wholesale distributorships in the field of pharmaceutical preparations for the treatment of allergies; wholesale distributorships in the field of cosmetics.ACTIVE—
042Research in the field of pharmacogenetics; research and development of gene-based pharmaceuticals; research and development in the field of gene expression systems; research in the field of gene therapy; research in the field of gene editing technologies; scientific research in the field of genetics; genetic testing for scientific research purposes; pharmaceutical research and development; research and development services in the field of cosmetics; food research.ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 29, 2026RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Sep 28, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 28, 2026DOCKASSIGNED TO EXAMINER—
Sep 10, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Sep 10, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 10, 2026REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance